Tempus Unicorn is a technology firm founded in 2015, Eric Lefkofsky being the co-founder and the Chief Executive Officer leading the organization in innovative technology operational system to battle the chronic cancer disease. Tempus uses manual curation, natural language processing, and optical character recognition to personalize care and improve cancer efficiency. The company focuses on the use of genomic sequencing to enable the specialized doctors to customize treatment of cancer.
CEO, Eric Lefkofsky has personally invested in the fundraising round for the company which has remained its most prominent individual investors throughout the years. On 20th March 2018, Groupon co-founder confirmed through the Chicago Business blog that Tempus received funds amounting to $80 million from new and existing investors who have been in forefront campaign of fighting cancer diseases. The investors that funded Tempus include Revolution Growth, New Enterprise Associates, and The New Investors Trust Co.
The company makes use of clinical data as a way of learning trends in cancer treatment and collecting molecular data from patients under treatment. Lefkofsky has initiated a partnership program with other organizations to help his company attain its objective in healthcare through bioinformatics, sequencing and machine learning. The expert team analyzes the datasets based on the relevant patterns to assist in identifying active immunotherapies given to cohorts of patients.
Healthcare data sets have been small and disorganized in oncology, technology has, therefore, open new opportunities for working with a mass amounts of clinical and molecular data to benefit cancer patients. Tempus has continuously grown through expansion of facilities, additionally; employees are hired to scale the size of the workers and clinical database. The development of Medical laboratories is purposely to accommodate the increasing number on a monthly basis.
The company has announced the collaboration with other cancer research hospitals including the University of Michigan, Duke University School of medicine, Mayo Clinic, The Cleveland Clinic, Northwestern University, University of Chicago, Knight Cancer Institute and The UC Davis Comprehensive Cancer Center. Tempus’ primary mission is to redefine genomic data usage in the clinical context that has improved its performance with other organizations where currently, it works with more than half of U.S Academic Medical Centers.
To Read More Click Here